229 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Capital Performance Advisors LLP

Capital Performance Advisors LLP acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 229 shares of the biotechnology company’s stock, valued at approximately $82,000.

Other large investors also recently bought and sold shares of the company. ClariVest Asset Management LLC raised its position in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of United Therapeutics during the second quarter worth $30,000. Innealta Capital LLC bought a new position in shares of United Therapeutics in the 2nd quarter worth about $33,000. USA Financial Formulas acquired a new position in shares of United Therapeutics in the 3rd quarter valued at about $33,000. Finally, Values First Advisors Inc. bought a new stake in shares of United Therapeutics during the 3rd quarter valued at about $90,000. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, Director Christopher Causey sold 510 shares of United Therapeutics stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the transaction, the director now owns 3,675 shares of the company’s stock, valued at $1,384,115.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director Christopher Causey sold 510 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the sale, the director now directly owns 3,675 shares of the company’s stock, valued at $1,384,115.25. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 14,700 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $374.46, for a total value of $5,504,562.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $964,983.42. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 96,422 shares of company stock valued at $35,251,428. 11.90% of the stock is owned by insiders.

United Therapeutics Price Performance

United Therapeutics stock opened at $410.00 on Friday. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The stock has a market capitalization of $18.31 billion, a PE ratio of 18.01, a price-to-earnings-growth ratio of 1.16 and a beta of 0.56. The firm has a 50 day simple moving average of $359.20 and a 200-day simple moving average of $322.16.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same period last year, the firm earned $5.38 EPS. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis. On average, analysts forecast that United Therapeutics Co. will post 25.1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent research reports. Jefferies Financial Group raised their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. The Goldman Sachs Group upped their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. TD Cowen raised their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Argus upped their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.